Taiwan Dr Jung-Chi Liao, CEO and Founder of Syncell, explains how his company is creating a new category in protein identification through its microscopy-guided protein extraction technology. Trained as a mechanical engineer with a PhD from MIT and later conducted biological research for 25 years since his postdoctoral work at Berkeley,…
Hong Kong Generative Artificial Intelligence (AI) has grabbed a lot of media attention in recent months following the launch of chatbot ChatGPT, but the pharmaceutical industry has long been trying – and struggling – to better integrate AI into the long and failure-fraught drug discovery process. While AI-enabled drug discovery may not…
China Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually set up a multifaceted platform for MNCs and biotechs. By having a manufacturing facility in the USA or Europe,…
AI Arthur Kadurin, CEO of Insilico Medicine Taiwan, tells us how artificial intelligence can change drug discovery process using the innovative generative adversarial networks (GANs) approach. AI is the future of the industry that has all the potential to transform and combat the complex drug discovery process. Please tell us…
Biotechnology The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic shift towards becoming a semi-virtual model company. He also considers the importance of creating global links to capital as a…
See our Cookie Privacy Policy Here
